{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-003814","form_type":"8-K","ticker":"SNDX","cik":"0001395937","company_name":"Syndax Pharmaceuticals Inc","filed_at":"2022-02-03T23:59:59+00:00","discovered_at":"2026-05-14T18:04:06.274539+00:00","generated_at":"2026-06-27T11:37:21.448772+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Syndax names Metzger CEO as Morrison moves to President, Head of R&D","bullets":["Michael Metzger appointed CEO, effective immediately; previously President & COO.","Briggs Morrison becomes President, Head of R&D; remains on board.","Metzger base salary $640,000, target bonus 60% of base; Morrison base $637,500, bonus up to 50%.","Transition aligns roles with expertise; Metzger to focus on strategic vision and commercial prep.","Morrison to focus on advancing SNDX-5613 and axatilimab toward NDA filings in 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-003814","json":"https://secwatch.observer/filing/0001564590-22-003814.json","markdown":"https://secwatch.observer/filing/0001564590-22-003814.md","text":"https://secwatch.observer/filing/0001564590-22-003814.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/sndx-8k_20220202.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-27T11:37:21.448772+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"71d0f15574","claim":"Briggs W. Morrison, M.D. changed role as President, Head of Research and Development at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On February 2, 2022, Briggs W. Morrison, M.D., transitioned from his role as Chief Executive Officer and principal executive officer of Syndax Pharmaceuticals, Inc. (the “ Company ”) to President, Head of Research and Development of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"transitioned"},{"label":"Role","value":"President, Head of Research and Development"}],"fact_type":"executive_change"},{"claim_id":"ee515c6799","claim":"Michael A. Metzger was appointed as Chief Executive Officer at Syndax Pharmaceuticals Inc.","evidence_excerpt":"On the same date, the Board appointed Michael A. Metzger, previously the Company’s President, Chief Operating Officer, and a member of the Board, to serve as the Company’s Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1395937/000156459022003814/0001564590-22-003814-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}